# Peginterferon beta-1a

## Plegridy inj 63mcg

##### 臨採

| 藥品代碼   | IPLE1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|:-----------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 適應症     | Plegridy is indicated in adult patients for the treatment of relapsing remitting multiple sclerosis.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 用法用量   | The recommended dose of Plegridy is 125 micrograms injected SC every 2 weeks (14 days). Treatment initiation: It is generally recommended that patients start SC treatment with 63 micrograms at dose 1 (on day 0)， increasing to 94 micrograms at dose 2 (on day 14)， reaching the full dose of 125 micrograms by dose 3 (on day 28) and continuing with the full dose (125 micrograms) every 2 weeks (14 days) thereafter.                                                                                                                                                                                                                                                                                                                                                                                            |
| 肝功能異常 | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 腎功能異常 | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 禁忌       | Hypersensitivity to natural or recombinant interferon beta or peginterferon or to any of the excipients. Patients with current severe depression and/or suicidal ideation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 副作用     | Common Dermatologic: Erythema at injection site (subQ， 25% to 62% )， Injection site pain (11% to 15% )， Injection site pruritus (13% ) Musculoskeletal: Arthralgia (11% ) Neurologic: Asthenia (13% )， Headache (36% to 44% ) Other: Fever (45% )， Influenza-like illness (47% )， Shivering (17% to 36% ) Serious Cardiovascular: Congestive heart failure Dermatologic: Injection site necrosis Hematologic: Decreased lymphocyte count (Less than 1% )， Decreased platelet count (Less than 1% )， Decreased white blood cell count (7% )， Neutropenia (Less than 1% )， Pancytopenia (Rare )， Thrombocytopenia Hepatic: Autoimmune hepatitis， Hepatitis， Liver failure Immunologic: Autoimmune disease (Less than 1% ) Neurologic: Seizure (Less than 1% ) Psychiatric: Suicidal thoughts Other: Angioedema |
| 孕期建議   | No (limited) human data – animal data suggest moderate risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 哺乳期建議 | Compatible 哺乳時可使用                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

## Plegridy inj 94mcg

##### 臨採

| 藥品代碼   | IPLE2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|:-----------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 適應症     | Plegridy is indicated in adult patients for the treatment of relapsing remitting multiple sclerosis.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 用法用量   | The recommended dose of Plegridy is 125 micrograms injected SC every 2 weeks (14 days). Treatment initiation: It is generally recommended that patients start SC treatment with 63 micrograms at dose 1 (on day 0)， increasing to 94 micrograms at dose 2 (on day 14)， reaching the full dose of 125 micrograms by dose 3 (on day 28) and continuing with the full dose (125 micrograms) every 2 weeks (14 days) thereafter.                                                                                                                                                                                                                                                                                                                                                                                            |
| 肝功能異常 | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 腎功能異常 | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 禁忌       | Hypersensitivity to natural or recombinant interferon beta or peginterferon or to any of the excipients. Patients with current severe depression and/or suicidal ideation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 副作用     | Common Dermatologic: Erythema at injection site (subQ， 25% to 62% )， Injection site pain (11% to 15% )， Injection site pruritus (13% ) Musculoskeletal: Arthralgia (11% ) Neurologic: Asthenia (13% )， Headache (36% to 44% ) Other: Fever (45% )， Influenza-like illness (47% )， Shivering (17% to 36% ) Serious Cardiovascular: Congestive heart failure Dermatologic: Injection site necrosis Hematologic: Decreased lymphocyte count (Less than 1% )， Decreased platelet count (Less than 1% )， Decreased white blood cell count (7% )， Neutropenia (Less than 1% )， Pancytopenia (Rare )， Thrombocytopenia Hepatic: Autoimmune hepatitis， Hepatitis， Liver failure Immunologic: Autoimmune disease (Less than 1% ) Neurologic: Seizure (Less than 1% ) Psychiatric: Suicidal thoughts Other: Angioedema |
| 孕期建議   | No (limited) human data – animal data suggest moderate risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 哺乳期建議 | Compatible 哺乳時可使用                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

## PLEGRIDY inj 125mcg

##### 臨採

| 藥品代碼   | IPLE3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|:-----------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 適應症     | Plegridy is indicated in adult patients for the treatment of relapsing remitting multiple sclerosis.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 用法用量   | The recommended dose of Plegridy is 125 micrograms injected SC every 2 weeks (14 days). Treatment initiation: It is generally recommended that patients start SC treatment with 63 micrograms at dose 1 (on day 0)， increasing to 94 micrograms at dose 2 (on day 14)， reaching the full dose of 125 micrograms by dose 3 (on day 28) and continuing with the full dose (125 micrograms) every 2 weeks (14 days) thereafter.                                                                                                                                                                                                                                                                                                                                                                                            |
| 肝功能異常 | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 腎功能異常 | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 禁忌       | Hypersensitivity to natural or recombinant interferon beta or peginterferon or to any of the excipients. Patients with current severe depression and/or suicidal ideation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 副作用     | Common Dermatologic: Erythema at injection site (subQ， 25% to 62% )， Injection site pain (11% to 15% )， Injection site pruritus (13% ) Musculoskeletal: Arthralgia (11% ) Neurologic: Asthenia (13% )， Headache (36% to 44% ) Other: Fever (45% )， Influenza-like illness (47% )， Shivering (17% to 36% ) Serious Cardiovascular: Congestive heart failure Dermatologic: Injection site necrosis Hematologic: Decreased lymphocyte count (Less than 1% )， Decreased platelet count (Less than 1% )， Decreased white blood cell count (7% )， Neutropenia (Less than 1% )， Pancytopenia (Rare )， Thrombocytopenia Hepatic: Autoimmune hepatitis， Hepatitis， Liver failure Immunologic: Autoimmune disease (Less than 1% ) Neurologic: Seizure (Less than 1% ) Psychiatric: Suicidal thoughts Other: Angioedema |
| 孕期建議   | No (limited) human data – animal data suggest moderate risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 哺乳期建議 | Compatible 哺乳時可使用                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

